DrugPatentWatch Database Preview

Details for Patent: 6,358,986

« Back to Dashboard

Which drugs does patent 6,358,986 protect, and when does it expire?

Patent 6,358,986 protects MICARDIS and MICARDIS HCT and is included in two NDAs.

This patent has forty-four patent family members in thirty-five countries.

Summary for Patent: 6,358,986

Title:	Polymorphs of telmisartan
Abstract:	The invention relates to polymorphs of 4'-[2-n-propyl-4-methyl-6-(1-methylbenzimid-azol-2-yl)benzimidazol-1-ylmet hyl]biphenyl-2-carboxylic acid (INN: telmisartan), particularly polymorphic form B, mixtures of the polymorphs, processes for preparing telmisartan containing form B and the use thereof for preparing a pharmaceutical composition.
Inventor(s):	Schneider; Heinrich (late of Ingelheim, DE)
Assignee:	Boehringer Ingelheim Pharma KG (Ingelheim, DE)
Application Number:	09/480,211
Patent Claim Types: see list of patent claims	Compound; Composition;

Drugs Protected by US Patent 6,358,986

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Boehringer Ingelheim	MICARDIS	telmisartan	TABLET;ORAL	020850-003	Apr 4, 2000	AB	RX	Yes	No
Boehringer Ingelheim	MICARDIS	telmisartan	TABLET;ORAL	020850-001	Nov 10, 1998	AB	RX	Yes	No
Boehringer Ingelheim	MICARDIS	telmisartan	TABLET;ORAL	020850-002	Nov 10, 1998	AB	RX	Yes	Yes
Boehringer Ingelheim	MICARDIS HCT	hydrochlorothiazide; telmisartan	TABLET;ORAL	021162-001	Nov 17, 2000	AB	RX	Yes	No

Foreign Priority and PCT Information for Patent: 6,358,986

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	199 01 921	Jan 19, 1999

Non-Orange Book US Patents Family Members for Patent 6,358,986

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
6,410,742	Polymorphs of telmisartan

International Patents Family Members for US Patent 6,358,986

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Slovakia	10202001
Slovenia	1144386
Saudi Arabia	584
Serbia	50044